EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 41 / Numéro 5 (Mai 2025) Med Sci (Paris), 41 5 (2025) 411-415 Références
Open Access
Numéro
Med Sci (Paris)
Volume 41, Numéro 5, Mai 2025
Enjeux et objectifs de la psychiatrie de précision
Page(s) 411 - 415
Section La psychiatrie de précision (PEPR PROPSY) : hypothèses et outils
DOI https://doi.org/10.1051/medsci/2025064
Publié en ligne 26 mai 2025
  1. Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010 ; 167 : 748–51. [CrossRef] [PubMed] [Google Scholar]
  2. Arns M, van Dijk H, Luykx JJ, et al. Stratified psychiatry: tomorrow’s precision psychiatry? Eur Neuropsychopharmacol 2022 ; 55 : 14–9. [CrossRef] [PubMed] [Google Scholar]
  3. Aisen P, Bateman RJ, Crowther D, et al. The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer’s disease based on clearcut biomarker evidence. Alzheimers Dement 2025 ; 21 : e14342. [CrossRef] [PubMed] [Google Scholar]
  4. Vieta E. Personalised medicine applied to mental health: precision psychiatry. Rev Psiquiatr Salud Ment 2015 ; 8 : 117–8. [CrossRef] [PubMed] [Google Scholar]
  5. Fernandes BS, Williams LM, Steiner J, et al. The new field of ‘precision psychiatry’. BMC Med 2017 ; 15 : 80. [CrossRef] [PubMed] [Google Scholar]
  6. Johansson A, Andreassen OA, Brunak S, et al. Precision medicine in complex diseases-Molecular subgrouping for improved prediction and treatment stratification. J Intern Med 2023 ; 294 : 378–96. [CrossRef] [PubMed] [Google Scholar]
  7. Williams LM. Decoding depression: integrating brain connectivity and symptom patterns to uncover major depressive disorder subtypes. Biol Psychiatry 2024 ; 96 : 415–6. [CrossRef] [PubMed] [Google Scholar]
  8. Lalousis PA, Malaviya A, Khatibi A, et al. Anhedonia as a potential transdiagnostic phenotype with immune-related changes in recent-onset mental health disorders. Biol Psychiatry 2024 ; 96 : 615–22. [CrossRef] [PubMed] [Google Scholar]
  9. Miller AH, Raison CL. Burning down the house: reinventing drug discovery in psychiatry for the development of targeted therapies. Mol Psychiatry 2023 ; 28 : 68–75. [CrossRef] [PubMed] [Google Scholar]
  10. Beam AL, Manrai AK, Ghassemi M. Challenges to the reproducibility of machine learning models in health care. JAMA 2020 ; 323 : 305–6. [CrossRef] [PubMed] [Google Scholar]
  11. Osimo EF, Stochl J, Zammit S, et al. Longitudinal population subgroups of CRP and risk of depression in the ALSPAC birth cohort. Compr Psychiatry 2020 ; 96 : 152143. [CrossRef] [PubMed] [Google Scholar]
  12. Krystal AD, Pizzagalli DA, Smoski M, et al. A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating kappa-opioid antagonism as a treatment for anhedonia. Nat Med 2020 ; 26 : 760–8. [CrossRef] [PubMed] [Google Scholar]
  13. Angrand L, Boukouaci W, Lajnef M, et al. Low peripheral mitochondrial DNA copy number during manic episodes of bipolar disorders is associated with disease severity and inflammation. Brain Behav Immun 2021 ; 98 : 349–56. [CrossRef] [PubMed] [Google Scholar]
  14. Zachos KA, Choi J, Godin O, et al. Mitochondrial biomarkers and metabolic syndrome in bipolar disorder. Psychiatry Res 2024 ; 339 : 116063. [CrossRef] [PubMed] [Google Scholar]
  15. Fleischhacker WW, Podhorna J, Groschl M, et al. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry 2021 ; 8 : 191–201. [CrossRef] [PubMed] [Google Scholar]
  16. Godin O, Etain B, Henry C, et al. Metabolic syndrome in a French cohort of patients with bipolar disorder: results from the FACE-BD cohort. J Clin Psychiatry 2014 ; 75 : 1078–85. [CrossRef] [PubMed] [Google Scholar]
  17. Godin O, Leboyer M, Gaman A, et al. Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: results from the FACE-SZ cohort. Schizophr Res 2015 ; 168 : 388–94. [CrossRef] [PubMed] [Google Scholar]
  18. Yang Y, Zhang X, Zhang Y, et al. Metformin treatment improves depressive symptoms associated with type 2 diabetes: A 24-week longitudinal study. J Affect Disord 2024 ; 365 : 80–6. [CrossRef] [PubMed] [Google Scholar]
  19. Martinez-Aran A, Vieta E. Precision psychotherapy. Eur Neuropsychopharmacol 2022 ; 55 : 20–1. [CrossRef] [PubMed] [Google Scholar]
  20. Holmes EA, Ghaderi A, Harmer CJ, et al. The Lancet psychiatry commission on psychological treatments research in tomorrow’s science. Lancet Psychiatry 2018 ; 5 : 237–86. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.